The Global Ventilator Associated Pneumonia Market size was valued at USD 988.2 Million in 2022 and is expected to surpass USD 2.46 Billion by 2031, expanding at a CAGR of 10.7% during the forecast period, 2023–2031. The growth of the market is attributed to the increasing incidence of ventilator-associated pneumonia.
Ventilator-associated pneumonia (VAP) is a form of lung infection that occurs to individuals who are on mechanical ventilation. The health condition is brought on by the prolonged treatment of neurological diseases, lung disorders, and trauma using ventilators. The prevalence of VAP is caused by a variety of parameters including reintubation, age and altered consciousness, supine position, and length of mechanical ventilation.
Early and precise identification of the disease is difficult but appropriate antibiotic treatment is urgently required once a patient is diagnosed with the disease. VAP diagnosis necessitates a high level of clinical suspicion, bedside examination, microbiologic investigation of respiratory secretions, and radiographic inspection.
Market Trends, Drivers, Restraints, and Opportunities
-
Wide prevalence of the illness and increasing incidence of traumatic brain injury are major factors driving the market.
-
Growing R&D investment for the discovery of better illness treatments by major players is fuelling the market.
-
Increasing number of the geriatric population and rising occurrence of hospital acquired illnesses are expected to propel the market in the coming years.
-
High ventilator charges and costly diagnostic testing are major challenges that can hinder the market growth during the forecast period.
-
Inappropriate reimbursement circumstances and side effects of treatment are predicted to hamper the market expansion in the coming years.
Scope of Ventilator Associated Pneumonia Market Report
The report on the global ventilator associated pneumonia includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Ventilator associated pneumonia Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Types (Immunity Therapy, Physiotherapy, and Prevention), Diagnoses (Clinical, Microbiological [Quantitative Cultures of Airway Specimens, Non-quantitative or Semi-quantitative Airway Sampling, and Blood & Pleural Fluid Cultures], Radiological, and Others), and End-users (Ambulatory Care Centres, Hospitals & Clinics, Research & Academic Institutes, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Nabriva Therapeutics plc; AstraZeneca; Bayer AG; WOCKHARDT; and Thermo Fisher Scientific.
|
Ventilator Associated Pneumonia Market Segment Insights
Prevention segment is projected to hold significant market share
Based on types, the ventilator associated pneumonia market is segmented into immunity therapy, physiotherapy, and prevention. The prevention segment is projected to hold significant market share as it entails monitoring, identifying, and reducing the risk factors of the disease. The physiotherapy segment, however, is anticipated to register a substantial growth rate in the coming years.
Physiotherapy is a type of therapy that uses physical exercise methods to cure and prevent diseases such as massage and manipulation. It also aids in the improvement of movement, function, and overall quality of life. Back pain, joint pain, neck discomfort, sports injuries, arthritis, and post-operative rehabilitation are all common conditions treated with physiotherapy.
Clinical segment is anticipated to account for substantial share
On the basis of diagnoses, the market is divided into clinical, microbiological, radiological, and others. The microbiological segment is categorized into quantitative cultures of airway specimens, non-quantitative or semi-quantitative airway sampling, and blood & pleural fluid cultures.
The clinical segment is anticipated to account for substantial share of the market owing to increasing incidence of the disease and rising patients visit to clinics for various clinical diagnosis.
Hospitals & clinics segment to register a rapid pace during the projection period
In terms of end-users, the ventilator associated pneumonia market is fragmented into ambulatory care centres, hospitals & clinics, research & academic institutes, and others. The hospitals & clinics segment is expected to register a rapid pace during the projection period due to the increasing population preference for hospitals over other medical settings due to price and availability of essential medical amenities in hospitals and clinics.
North America is expected to dominate the market
In terms of regions, the market is classified as Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is expected to dominate the market due the prevalence of the disease and expanding government and non-government initiatives or measures to restrict the disease spread. The existence of a big patient population with lung disorders as well as increasing expansion of well-developed healthcare facilities present another key drivers of the regional market growth.
Furthermore, increased public awareness of the disease that result to wide adoption of early detection as well as rising number of respiratory and infectious disorders are expected to fuel the market in the region. Other factors contributing to North America's dominance in the market include favorable reimbursement regulations and widespread acceptance of sophisticated technologies.
Segments
The global ventilator associated pneumonia market has been segmented on the basis of
Types
- Immunity Therapy
- Physiotherapy
- Prevention
Diagnoses
- Clinical
- Microbiological
- Quantitative Cultures of Airway Specimens
- Non-quantitative or Semi-quantitative Airway Sampling
- Blood & Pleural Fluid Cultures
- Radiological
- Others
End-users
- Ambulatory Care Centres
- Hospitals & Clinics
- Research & Academic Institutes
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the global ventilator associated pneumonia market are Nabriva Therapeutics plc; AstraZeneca; Bayer AG; WOCKHARDT; and Thermo Fisher Scientific. These players are actively engaged in various market development activities including collaborations, agreements, mergers & acquisitions, production capacity expansion, new product launches, and partnerships to increase their market share.
Request For Customization
Enquiry Before Buying
Speak With Analyst
